The case for & against
Bull & Bear analysis
Bullish
ImmuCell Corporation (NASDAQ: ICCC) specializes in developing innovative products for livestock health, particularly focusing on calf health solutions in the animal health diagnostics sector. Notably, the company is recognized for its lead product, First Defense, which aims to prevent calf scours, reflecting a growing market segment increasingly valuing preventative health measures due to rising calf values.
Bull says
- ↑Q1 2026 revenue hit $10.4M, up 28.4% YoY—the first $10M quarter
- ↑Gross margin improved to 45% from 41.6% YoY via higher yields and pricing
- ↑Domestic sales reached $9.7M (+35.7% YoY), U.S. share rose to 35.2%
- ↑Ended Q1 with $6.8M cash and $2M settlement earmarked for capacity expansion
- ↑Addressable U.S. prevention market >$200M underpins long-term growth
- ↑High profitability and positive earnings revisions support bullish momentum
Bear says
- ↓International revenue fell 30.2% in Q1, highlighting export weaknesses
- ↓FDA approval delays for Retain could defer key product launches
- ↓Manufacturing capacity constraints risk slower fulfillment amid rising demand
- ↓Rising opex and supply-chain pressures may compress gross margins
- ↓Negative earnings yield and weak growth factor imply valuation risk
- ↓Elevated short interest signals investor skepticism and potential volatility
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-20-2026bullish
Transcript signals
Bull points
- We achieved our first ever $10 million revenue quarter, which is an exciting milestone for our commercial team and our manufacturing team.
- We also grew net income 34% compared to the first quarter of 2025.
- we believe we're gaining share in this market, competing against the world's largest animal health companies.
Bear points
- declined 30.2% to about $600,000 in the same period.
- Other expense decreased to $15,000 in the first quarter of 2026 compared to $330,000 of other income in the first quarter of 2025. This was driven by a non-recurring insurance payment in the first quarter of 2025.
Read full transcript analysis ›